{"success":true,"data":{"pressRelease":{"id":"153024","rtpr_id":"nNFC3M6Gp9-20260925","ticker":"CHCRF","exchange":"OTC","all_tickers":["CHCRF","CHER"],"title":"Cheelcare Announces First Quarter Fiscal 2027 Financial Results","author":"Newsfile Corp","published_at":"2026-09-25T12:00:17.506Z","article_body":"Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc.\n(TSXV: CHER) (OTC: CHCRF) (\"Cheelcare\" or the \"Company\"), a Canadian innovator\nin advanced mobility solutions, today announced its financial results for the\nthree months ended July 31, 2026. All figures are in CAD unless otherwise\nnoted.\n\nOperational Highlights (Three Months Ended July 31, 2026)\n* Companion reimbursement and market access: The Company continued to advance\nCompanion's U.S. commercialization following PDAC verification and Medicare\nand Medicaid reimbursement eligibility received in January 2026, with\nincreased engagement across its dealer, clinician and funding networks.\n* Canadian patent issued for Companion platform: In May 2026, the Canadian\nIntellectual Property Office granted Canadian Patent No. 3,090,535 covering\ncore technologies underlying the Companion power-assist platform. The patent\ncomplements the Company's existing U.S. patent protection and provides\nadditional intellectual property protection for Companion in North America.\n* $3.02 million private placement completed: On July 3, 2026, Cheelcare\ncompleted an upsized private placement for gross proceeds of $3.02 million,\nproviding additional capital to support commercialization, product development\nand working capital.\n* Curio engineering and regulatory work continued: Cheelcare continued\nengineering and validation activities for Curio in support of a future\nresubmission under Ontario's Assistive Devices Program and continued to\nadvance the U.S. FDA 510(k) process. Cybersecurity testing for Curio has been\ncompleted.\n* Numotion Commercial Growth Summit: Subsequent to quarter-end, Cheelcare\nparticipated in Numotion's Commercial Growth Summit in Denver, presenting\nCompanion to clinicians, Assistive Technology Professionals and other\ndecision-makers within one of North America's largest Complex Rehab Technology\nnetworks.\nFirst Quarter Financial Highlights (Three Months Ended July 31, 2026)\n* Revenue of $828,516, compared to $417,981 in Q1 fiscal 2026, representing an\nincrease of approximately 98%.\n* Gross profit of $481,637, representing a gross margin of 58.1%, compared to\na gross profit of $212,787 and a gross margin of 50.9% in Q1 fiscal 2026.\n* Net loss of $501,008, or $0.02 per share, compared to a net loss of\n$1,630,108, or $0.15 per share, in Q1 fiscal 2026. The prior-year period\nincluded a significant listing expense associated with the Company's reverse\ntakeover.\n* Cash and cash equivalents of $2.4 million at July 31, 2026, compared with\n$163,416 at April 30, 2026.\nSubsequent to quarter-end, the Company repaid its outstanding bank loans with\nthe Business Development Bank of Canada in full.\n\n\"Q1 is the first full quarter where we are beginning to see the commercial\nimpact of Companion's Medicare and Medicaid reimbursement eligibility in the\nUnited States, which was received in January 2026,\" said Eugene Cherny, CEO of\nCheelcare. \"That expanded access, together with the growth of our dealer and\nclinician network, is creating more opportunities to put Companion in the\nhands of users who can benefit from it. Our focus now is on converting that\nbroader reimbursement access and distribution footprint into sustained\nCompanion growth, continuing to improve manufacturing efficiency as volumes\nincrease, and advancing Curio through the engineering, validation and\nregulatory work required for broader commercialization.\"\n\nAbout Cheelcare Inc.\nCheelcare designs and manufactures innovative mobility solutions that empower\nindependence for people with disabilities. From the Companion power assist\ndevices to the groundbreaking Curio robotic complex-rehab power wheelchair,\nCheelcare combines engineering excellence with human-centered design to\nimprove quality of life. For more information, please visit: www.cheelcare.ca.\n\nFor further information, please contact:\nSofiya Kagan, Director of Marketing\nCheelcare Inc.\nTel: 1-888-948-2680 x 206\nEmail: skagan@cheelcare.com\n\nForward-Looking Information:\nThis news release may contain forward-looking statements. Forward-looking\nstatements are based on current expectations and involve known and unknown\nrisks, uncertainties, and other factors that may cause actual results or\nevents to differ materially from those expressed or implied. Such factors\ninclude, but are not limited to, general economic conditions, market demand,\nsupply chain disruptions, and regulatory approvals. Any forward-looking\nstatements are made as of the date of this news release, and the Company does\nnot undertake to update any forward-looking statements except in accordance\nwith applicable securities laws.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316019","article_body_html":"","raw_payload":{"data":{"id":"nNFC3M6Gp9-20260925","title":"Cheelcare Announces First Quarter Fiscal 2027 Financial Results","author":"Newsfile Corp","ticker":"CHCRF","created":"2026-09-25T12:00:17.506Z","tickers":["CHCRF","CHER"],"exchange":"OTC","article_body":"Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc.\n(TSXV: CHER) (OTC: CHCRF) (\"Cheelcare\" or the \"Company\"), a Canadian innovator\nin advanced mobility solutions, today announced its financial results for the\nthree months ended July 31, 2026. All figures are in CAD unless otherwise\nnoted.\n\nOperational Highlights (Three Months Ended July 31, 2026)\n* Companion reimbursement and market access: The Company continued to advance\nCompanion's U.S. commercialization following PDAC verification and Medicare\nand Medicaid reimbursement eligibility received in January 2026, with\nincreased engagement across its dealer, clinician and funding networks.\n* Canadian patent issued for Companion platform: In May 2026, the Canadian\nIntellectual Property Office granted Canadian Patent No. 3,090,535 covering\ncore technologies underlying the Companion power-assist platform. The patent\ncomplements the Company's existing U.S. patent protection and provides\nadditional intellectual property protection for Companion in North America.\n* $3.02 million private placement completed: On July 3, 2026, Cheelcare\ncompleted an upsized private placement for gross proceeds of $3.02 million,\nproviding additional capital to support commercialization, product development\nand working capital.\n* Curio engineering and regulatory work continued: Cheelcare continued\nengineering and validation activities for Curio in support of a future\nresubmission under Ontario's Assistive Devices Program and continued to\nadvance the U.S. FDA 510(k) process. Cybersecurity testing for Curio has been\ncompleted.\n* Numotion Commercial Growth Summit: Subsequent to quarter-end, Cheelcare\nparticipated in Numotion's Commercial Growth Summit in Denver, presenting\nCompanion to clinicians, Assistive Technology Professionals and other\ndecision-makers within one of North America's largest Complex Rehab Technology\nnetworks.\nFirst Quarter Financial Highlights (Three Months Ended July 31, 2026)\n* Revenue of $828,516, compared to $417,981 in Q1 fiscal 2026, representing an\nincrease of approximately 98%.\n* Gross profit of $481,637, representing a gross margin of 58.1%, compared to\na gross profit of $212,787 and a gross margin of 50.9% in Q1 fiscal 2026.\n* Net loss of $501,008, or $0.02 per share, compared to a net loss of\n$1,630,108, or $0.15 per share, in Q1 fiscal 2026. The prior-year period\nincluded a significant listing expense associated with the Company's reverse\ntakeover.\n* Cash and cash equivalents of $2.4 million at July 31, 2026, compared with\n$163,416 at April 30, 2026.\nSubsequent to quarter-end, the Company repaid its outstanding bank loans with\nthe Business Development Bank of Canada in full.\n\n\"Q1 is the first full quarter where we are beginning to see the commercial\nimpact of Companion's Medicare and Medicaid reimbursement eligibility in the\nUnited States, which was received in January 2026,\" said Eugene Cherny, CEO of\nCheelcare. \"That expanded access, together with the growth of our dealer and\nclinician network, is creating more opportunities to put Companion in the\nhands of users who can benefit from it. Our focus now is on converting that\nbroader reimbursement access and distribution footprint into sustained\nCompanion growth, continuing to improve manufacturing efficiency as volumes\nincrease, and advancing Curio through the engineering, validation and\nregulatory work required for broader commercialization.\"\n\nAbout Cheelcare Inc.\nCheelcare designs and manufactures innovative mobility solutions that empower\nindependence for people with disabilities. From the Companion power assist\ndevices to the groundbreaking Curio robotic complex-rehab power wheelchair,\nCheelcare combines engineering excellence with human-centered design to\nimprove quality of life. For more information, please visit: www.cheelcare.ca.\n\nFor further information, please contact:\nSofiya Kagan, Director of Marketing\nCheelcare Inc.\nTel: 1-888-948-2680 x 206\nEmail: skagan@cheelcare.com\n\nForward-Looking Information:\nThis news release may contain forward-looking statements. Forward-looking\nstatements are based on current expectations and involve known and unknown\nrisks, uncertainties, and other factors that may cause actual results or\nevents to differ materially from those expressed or implied. Such factors\ninclude, but are not limited to, general economic conditions, market demand,\nsupply chain disruptions, and regulatory approvals. Any forward-looking\nstatements are made as of the date of this news release, and the Company does\nnot undertake to update any forward-looking statements except in accordance\nwith applicable securities laws.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316019"},"type":"article","timestamp":"2026-09-25T12:00:17.55891828Z","server_sent_at_ms":1790337617558},"received_at":"2026-09-25T12:00:17.618Z","source_url":"https://www.newsfilecorp.com/release/316019"},"analysis":{"id":"141826","press_release_id":"153024","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["very small absolute revenue base (~$829K CAD) — growth rate overstates scale","still unprofitable with modest $2.4 million cash position post-raise"],"eventType":"earnings","narrative":"Cheelcare reported Q1 fiscal 2027 revenue of $828,516 CAD, up roughly 98% year-over-year, with gross margin expanding to 58.1% from 50.9%.\n\nNet loss narrowed to $501,008 ($0.02 per share) from $1,630,108 ($0.15 per share), and cash rose to $2.4 million after a $3.02 million private placement; bank loans with BDC were repaid in full after quarter-end.\n\nGrowth reflects Companion's U.S. Medicare and Medicaid reimbursement eligibility received in January 2026, plus a newly issued Canadian patent; the company is also advancing Curio's FDA 510(k) process.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Reimbursement-driven inflection: ~98% revenue growth and margin expansion for micro-cap mobility innovator Cheelcare."},"keyFigures":{"revenue":828516,"revenueYoy":"98%","customDimensions":{"currency":"CAD","net_loss":501008,"gross_margin":"58.1%","gross_profit":481637,"prior_year_net_loss":1630108,"cash_and_equivalents":"$2.4 million","prior_year_gross_margin":"50.9%","private_placement_gross_proceeds":"$3.02 million"}},"quotedText":"Q1 is the first full quarter where we are beginning to see the commercial impact of Companion's Medicare and Medicaid reimbursement eligibility in the United States, which was received in January 2026","namedEntities":{"people":[{"name":"Eugene Cherny","role":"CEO"},{"name":"Sofiya Kagan","role":"Director of Marketing"}],"products":["Companion","Curio"],"companies":[{"name":"Cheelcare Inc.","ticker":"CHCRF","relationship":"filer"},{"name":"Business Development Bank of Canada","relationship":"lender"},{"name":"Numotion","relationship":"distribution partner"}],"dollarAmounts":[{"amount":"$828,516","context":"Q1 fiscal 2027 revenue (CAD)"},{"amount":"$417,981","context":"Q1 fiscal 2026 revenue (CAD)"},{"amount":"$501,008","context":"Q1 fiscal 2027 net loss (CAD)"},{"amount":"$1,630,108","context":"Q1 fiscal 2026 net loss (CAD)"},{"amount":"$3.02 million","context":"private placement gross proceeds (CAD)"},{"amount":"$2.4 million","context":"cash and cash equivalents at July 31, 2026 (CAD)"},{"amount":"$163,416","context":"cash at April 30, 2026 (CAD)"}]},"materialImpact":{"score":3,"reasoning":"Micro-cap issuer reports ~98% YoY revenue growth, expanding gross margin (58.1% vs 50.9%), and sharply lower net loss following U.S. Medicare/Medicaid reimbursement for Companion. Material operational inflection, but on a small revenue base of ~$829K CAD."},"tickerRelevance":{"others":[],"primary":"CHCRF"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap OTC","eventGravity":"micro-cap earnings with strong growth rate","revenueScale":"sub-$1M quarterly revenue","commercialMilestone":"Medicare/Medicaid reimbursement ramp"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Cheelcare reported Q1 fiscal 2027 revenue of $828,516 CAD, up roughly 98% year-over-year, with gross margin expanding to 58.1% from 50.9%.\n\nNet loss narrowed to $501,008 ($0.02 per share) from $1,630,108 ($0.15 per share), and cash rose to $2.4 million after a $3.02 million private placement; bank loans with BDC were repaid in full after quarter-end.\n\nGrowth reflects Companion's U.S. Medicare and Medicaid reimbursement eligibility received in January 2026, plus a newly issued Canadian patent; the company is also advancing Curio's FDA 510(k) process.","key_figures":{"revenue":828516,"revenueYoy":"98%","customDimensions":{"currency":"CAD","net_loss":501008,"gross_margin":"58.1%","gross_profit":481637,"prior_year_net_loss":1630108,"cash_and_equivalents":"$2.4 million","prior_year_gross_margin":"50.9%","private_placement_gross_proceeds":"$3.02 million"}},"named_entities":{"people":[{"name":"Eugene Cherny","role":"CEO"},{"name":"Sofiya Kagan","role":"Director of Marketing"}],"products":["Companion","Curio"],"companies":[{"name":"Cheelcare Inc.","ticker":"CHCRF","relationship":"filer"},{"name":"Business Development Bank of Canada","relationship":"lender"},{"name":"Numotion","relationship":"distribution partner"}],"dollarAmounts":[{"amount":"$828,516","context":"Q1 fiscal 2027 revenue (CAD)"},{"amount":"$417,981","context":"Q1 fiscal 2026 revenue (CAD)"},{"amount":"$501,008","context":"Q1 fiscal 2027 net loss (CAD)"},{"amount":"$1,630,108","context":"Q1 fiscal 2026 net loss (CAD)"},{"amount":"$3.02 million","context":"private placement gross proceeds (CAD)"},{"amount":"$2.4 million","context":"cash and cash equivalents at July 31, 2026 (CAD)"},{"amount":"$163,416","context":"cash at April 30, 2026 (CAD)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-25T12:00:24.827Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap OTC","eventGravity":"micro-cap earnings with strong growth rate","revenueScale":"sub-$1M quarterly revenue","commercialMilestone":"Medicare/Medicaid reimbursement ramp"}},"durationMs":7199,"modelName":"glm-5.3-flashx"}}